Abnormal Thyroid Levels in Lymphoma: What They Mean and When to Worry

Abnormal thyroid tests in people with lymphoma are fairly common, especially during modern treatments like immunotherapy, and they are usually manageable with routine monitoring and simple medications. In many cases, thyroid changes reflect a temporary inflammation or an immune‑related side effect of therapy rather than cancer worsening. [PM13] ^[1]

---

Why thyroid levels can change in lymphoma

• Immune checkpoint inhibitors (ICIs) can trigger thyroid dysfunction. Drugs such as nivolumab or pembrolizumab used in some Hodgkin and non‑Hodgkin lymphoma regimens can lead to thyroiditis (inflammation), hyperthyroidism (overactive thyroid), or hypothyroidism (underactive thyroid). This is one of the most frequent endocrine side effects of PD‑1/PD‑L1 inhibitors. [PM13] [PM21]

• Real‑world data show thyroid issues are not rare. In a national safety registry of nivolumab in classic Hodgkin lymphoma, thyroid dysfunction occurred in about 9–10% of treated individuals, and hypothyroidism was specifically reported in approximately 5%. This suggests thyroid changes are a recognized, monitored event during ICI therapy. [PM19]

• CAR‑T cell therapy can rarely be associated with autoimmune thyroiditis. Case reports describe Hashimoto’s thyroiditis developing after CD19 CAR‑T in diffuse large B‑cell lymphoma, likely due to immune activation. While uncommon, clinicians are aware and can test and treat if symptoms or labs suggest it. [PM14]

• Other cancer treatments and prior conditions may play a role. Some chemotherapy or transplant histories can affect thyroid long‑term, even without radiation, though patterns vary; care teams watch for delayed thyroid issues in survivors. [PM16]

---

What the abnormal tests might mean

• Thyroiditis pattern (immune‑related): Often starts with a brief hyperthyroid phase (low TSH, high free T4), then shifts to hypothyroidism (high TSH, low/normal free T4). This course is typical of treatment‑related thyroiditis and may stabilize over time. ^[1] [PM21]

• Overt hypothyroidism: Persistently high TSH with low free T4 generally needs thyroid hormone replacement (levothyroxine). Replacement is effective and allows cancer therapy to continue in most cases. ^[2] [PM21]

• Hyperthyroidism: Symptoms like palpitations, heat intolerance, tremor may accompany low TSH/high free T4. Beta‑blockers help control symptoms, and short courses of steroids are sometimes considered if symptoms don’t settle, depending on severity. ^[3]

---

Symptoms to watch for

• Hypothyroidism: Fatigue, feeling cold, weight gain, dry skin, constipation, slowed thinking. These can be subtle; regular labs help catch changes early. ^[4]

• Hyperthyroidism: Rapid heartbeat, heat intolerance, nervousness, trouble sleeping, frequent bowel movements, weight loss. Report these promptly during treatment. ^[4]

Rarely, severe hypothyroidism can escalate to a “myxedema crisis,” a medical emergency; this has been reported with PD‑1 therapy, but it is uncommon and treatable when recognized early. [PM20]

---

How your care team monitors and manages it

• Routine blood tests during immunotherapy. TSH and free T4 are typically checked every 4–6 weeks during ICI treatment, sometimes every cycle early on, because thyroid changes can appear early or late. Monitoring continues periodically even after therapy ends, since delayed endocrine effects can occur. ^{[5] [6]}

• If thyrotoxicosis (overactive thyroid) is suspected: T3 and antibody tests (TSH receptor antibodies, anti‑TPO) may be added to distinguish temporary thyroiditis from Graves’ disease. This helps tailor treatment. ^{[5] [6]}

• Grading and treatment approach: Mild (grade 1) dysfunction is often managed with supportive care and endocrine input if persistent; moderate (grade 2) may warrant endocrinology referral and medication; severe cases require more intensive management, but stopping cancer therapy is not always necessary. Plans are individualized to keep you on track with lymphoma treatment whenever safely possible. ^{[3] [4]}

---

Does this mean the lymphoma is worse?

• Usually no. Treatment‑related thyroid changes reflect immune effects on the thyroid, not lymphoma progression. Cancer response can continue despite thyroid side effects, and simple measures usually control thyroid issues. [PM13] [PM19]

• Imaging clues can align with thyroiditis. Clinicians sometimes see increased uptake in the thyroid on PET/CT that later resolves, consistent with transient inflammation rather than new cancer. This pattern supports a benign, treatment‑related process. ^[2]

---

When to be concerned and what to do

• Call your team if you have new heart palpitations, severe fatigue, dizziness, or shortness of breath. These could signal significant thyroid imbalance needing prompt adjustment. Early communication helps avoid complications and keeps your cancer care on schedule. ^{[3] [4]}

• Bring up any past thyroid issues. Prior thyroid disease can raise the risk of dysfunction during ICI therapy, so your team may monitor more closely and plan ahead. Sharing your history helps personalize care. [PM19]

---

Practical tips

• Keep a symptom diary (energy, sleep, heart rate, temperature sensitivity, bowel habits).
• Take thyroid medication at the same time daily, away from calcium/iron supplements to improve absorption.
• Ask about your target TSH range during replacement therapy, especially if you are on or between treatment cycles.
• If hyperthyroid symptoms arise, avoiding excess caffeine and using prescribed beta‑blockers can ease discomfort while the thyroiditis phase settles. ^[3]

---

Bottom line

Abnormal thyroid levels during lymphoma care are common and usually manageable, especially with immunotherapy‑related thyroiditis. With regular blood tests and timely symptom reporting, most people stay safely on their lymphoma treatment, using simple thyroid medicines when needed. [PM13] [PM19] [PM21] ^{[5] [6] [3] [4] [2]}

---